Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis

Clinical Rheumatology

Volumn 36, Issue 2, 2017, Pages 241-250

  Kihara, Mari ^a,b   Davies, Rebecca ^a   Kearsley Fleet, Lianne ^a   Watson, Kath D ^a   Lunt, Mark ^a   Symmons, Deborah P M ^a,c   Hyrich, Kimme L ^a,c   on behalf of the British Society for Rheumatology Biologics Register, ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d NONE

Author keywords

Biological disease modifying anti rheumatic drugs (bDMARDs); Observational study; Rheumatoid arthritis; Tocilizumab; Treatment outcome; Treatment selection

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG USE; FEMALE; HISTORY; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL SOCIETY; OBSERVATIONAL STUDY; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; FOLLOW UP; MIDDLE AGED; NEOPLASMS; PULMONARY FIBROSIS; REGRESSION ANALYSIS; TIME FACTOR; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; REGISTRIES; REGRESSION ANALYSIS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED KINGDOM;

EID: 85000995849     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3485-5     Document Type: Article

References (39)

1. Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916
2. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509
3. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, Tagaki N, Kishimoto T (2003) Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with. J Rheumatol 30:1426–1435
4. NICE (2010) Tocilizumab for the treatment of rheumatoid arthritis. NICE Technol. Apprais. Guid. 198
5. NICE (2012) Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198). In: NICE Technol. Apprais. Guid. 247. https://www.nice.org.uk/guidance/ta247
6. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541–1550. doi:10.1016/S0140-6736(13)60250-0
7. Backhaus M, Kaufmann J, Richter C, Wassenberg S, Roske A-E, Hellmann P, Gaubitz M (2015) Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol. doi:10.1007/s10067-015-2879-0
8. Kaufmann J, Feist E, Roske AE, Schmidt W a (2013) Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 32:1347–1355. doi:10.1007/s10067-013-2281-8
9. Romão VC, Santos MJ, Polido-Pereira J, Duarte C, Nero P, Miguel C, Costa JA, Bernardes M, Pimentel-Santos FM, Barcelos F, Costa L, António J, Gomes M, Alberto J, Branco JC, Canas J, António J, Fonseca JE, Canhão H (2015) Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients: data from the Rheumatic Diseases Portuguese Register, Reuma. pt. 2015
10. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, Yamanaka H (2014) Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41:15–23. doi:10.3899/jrheum.130466
11. Balsa A, Tovar Beltran JV, Caliz Caliz R, Mateo Bernardo I, Garcia-Vicun AR, Rodriguez-Gomez M, Belmonte Serrano MA, Marras C, Loza Cortina E, Perez-Pampin E, Vila V (2015) Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatol Int 35:1525–1534. doi:10.1007/s00296-015-3237-x
12. Narváez J, Magallares B, Díaz Torné C, Hernández MV, Reina D, Corominas H, Sanmartí R, LLobet JM, Rodriguez de la Serna A, Nolla JM (2015) Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum 45:1–5. doi:10.1016/j.semarthrit.2015.07.001
13. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O, Bernasconi C, Huizinga TWJ (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73:803–809. doi:10.1136/annrheumdis-2013-204761
14. Huizinga TWJ, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M (2015) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74:35–43. doi:10.1136/annrheumdis-2014-205752
15. Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K (2016) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). 1–7. doi: 10.1136/annrheumdis-2015-208426
16. Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N (2015) Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford) 54:113–120. doi:10.1093/rheumatology/keu302
17. Gabay C, Riek M, Hetland ML, Hauge E-M, Pavelka K, Tomšič M, Canhao H, Chatzdionysiou K, Lukina G, Nordström DC, Lie E, Ancuta I, Hernández MV, van Riel PLMC, van Vollenhoven R, Kvien TK (2015) Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis annrheumdis 2015:207760. doi:10.1136/annrheumdis-2015-207760
18. Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, Takeuchi T (2015) Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective. Mod Rheumatol 25:31–37. doi:10.3109/14397595.2014.897793
19. Bruce B, Fries JF (2005) The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 23:S14–S18
20. van Gestel a M, Prevoo ML, van’t Hof M a, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40. doi:10.1002/art.1780390105
21. van Riel PL, van Gestel a M (2000) Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59(Suppl 1):i28–i31. doi:10.1136/ard.59.suppl_1.i28
22. Beaton DE, Bombardier C, Katz JN, Wright JG, Wells G, Boers M, Strand V, Shea B (2001) Looking for important change/differences in studies of responsiveness. J Rheumatol 28:400–405
23. Fransen J, Stucki G, van Riel PLCM (2003) Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 49:S214–S224. doi:10.1002/art.11407
24. Cole SR, Hernan MA (2008) Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168:656–664. doi:10.1093/aje/kwn164
25. Ramos-Casals M, Perez-Alvarez R, Perez-De-Lis M, Xaubet A, Bosch X (2011) Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 124:386–394. doi:10.1016/j.amjmed.2010.11.028
26. Mercer LK, Lunt M, Low ALS, Dixon WG, Watson KD, Symmons DPM, Hyrich KL (2014) Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis:1–7. doi:10.1136/annrheumdis-2013-204851
27. Khasnis AA, Calabrese LH (2010) Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 40:147–163. doi:10.1016/j.semarthrit.2009.09.001
28. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285. doi:10.1001/jama.295.19.2275
29. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F, Finney D, Dixey J, Deighton C (2010) BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 49:2217–2219. doi:10.1093/rheumatology/keq249a
30. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13:R141. doi:10.1186/ar3455
31. Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T (2016) Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case???Control study. Rheumatol Int 36:881–889. doi:10.1007/s00296-016-3478-3
32. Yoshida K, Tokuda Y, Oshikawa H, Utsunomiya M, Kobayashi T, Kimura M, Deshpande G a, Matsui K, Kishimoto M (2011) An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford) 50:2093–2099. doi:10.1093/rheumatology/ker295
33. Hyrich KL, Symmons DPM, Watson KD, Silman AJ (2006) Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:1786–1794. doi:10.1002/art.21830
34. Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A (2015) Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 67:2011–2019. doi:10.1002/art.39169
35. Smolen JS, Aletaha D (2011) Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 63:43–52. doi:10.1002/art.27740
36. Kawashiri S-Y, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Ueki Y, Migita K, Mizokami A, Origuchi T, Aoyagi K, Eguchi K (2011) Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol 21:365–369. doi:10.1007/s10165-010-0402-7
37. Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T (2009) Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol 19:507–512. doi:10.1007/s10165-009-0203-z
38. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 66:407–409. doi:10.1136/ard.2006.054205
39. Akiyama M, Kaneko Y, Kondo H, Takeuchi T (2016) Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Clin Rheumatol:1–6. doi:10.1007/s10067-016-3227-8